- Home
- OCCI vs SLGL Comparison
OCCI vs SLGL Comparison
Compare OCCI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OCCI | SLGL |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.4M | 117.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OCCI | SLGL |
|---|---|---|
| Price | $4.52 | $42.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 115.8K | 15.3K |
| Earning Date | 12-11-2023 | 11-20-2025 |
| Dividend Yield | ★ 24.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | $10.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $5.47 | $4.02 |
| 52 Week High | $10.15 | $52.26 |
Technical Indicators
Market Signals| Indicator | OCCI | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 57.44 |
| Support Level | $4.75 | $38.30 |
| Resistance Level | $5.09 | $44.43 |
| Average True Range (ATR) | 0.14 | 3.59 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 6.15 | 68.45 |
Price Performance
Historical ComparisonAbout OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.